The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

NIAB scientists in Hyderabad develop innovative diagnostic tests for antibiotics in animal food samples, enhancing food ...

After CEO Kevin Lobo promised earlier this summer a “bullish” M&A pipeline, Stryker is following through with its seventh ...

GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.

Hardware chain Total Tools has suffered a major data leak that is believed to have impacted 38,000 customers covering credit ...

Parse raised $50 million in December. The company had more than 100 employees at the time, with about 70% of them based in ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Almaden—which was formerly part of IBM Research before launching as a standalone company in 2022 under Catalyze Dallas ...

Update on FDA's Applied Therapeutics, Inc. decision to remove advisory panel for govorestat review in treating galactosemia.

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

Zymo Research Corporation, a leader in innovative life science solutions, acknowledges the patent infringement lawsuit filed ...

Learn more about whether Arcellx Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on AAII's A+ Investor ...